76
Participants
Start Date
January 22, 2020
Primary Completion Date
January 14, 2022
Study Completion Date
February 7, 2023
Capmatinib
INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
Pembrolizumab
Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
Novartis Investigative Site, Wollongong
Novartis Investigative Site, Shepparton
Novartis Investigative Site, North Adelaide
Novartis Investigative Site, Yvoir
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Athens
Novartis Investigative Site, Berlin
Novartis Investigative Site, Madrid
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Aviano
Novartis Investigative Site, Taichung
Novartis Investigative Site, Valencia
Novartis Investigative Site, Changhua
Novartis Investigative Site, Cologne
Novartis Investigative Site, Thessaloniki
Novartis Investigative Site, Lille
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Ancona
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Kuching
Novartis Investigative Site, Mumbai
Novartis Investigative Site, Kolkata
Novartis Investigative Site, Québec
Novartis Investigative Site, Ostrava Vitkovice
Novartis Investigative Site, Shatin New Territories
Novartis Investigative Site, Delhi
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Amersfoort
Novartis Investigative Site, Breda
Novartis Investigative Site, Zwolle
Novartis Investigative Site, Badalona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY